Search

everythinglearnresearchcommunity

for

Search:↓

Hair follicles may help teach the immune system to tolerate new self-antigens, but this can sometimes cause hair loss.

People with primary immunodeficiencies often have frequent, severe, or unusual infections and may need special tests and management strategies.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

Plucked hair can help diagnose pemphigus vulgaris early.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.

A patient's skin rash did not affect the area where a previous viral rash was healing, suggesting a rare immune response.

Immunological treatment improved both neuropathy and alopecia.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

Anti-CD19 therapy may help treat SLE and NMOSD.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Live vaccines can be safely given to infants with a FOXN1 variant if their immune function improves over time.

More precise, personalized therapies are needed for autoimmune diseases.

Lighter skin types respond better to narrowband UVB therapy for cutaneous T-cell lymphoma than darker skin types.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

T-cells in alopecia areata scalp show abnormal regulation, leading to less inflammation.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.

Moderate immune responses help hair growth, while excessive responses slow it down.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

Hair growth phase in mice weakens certain immune responses.